Ertugliflozin Shows Better Renal Outcomes in diabetes patients with atherosclerotic CVD MD Bureau20 March 2021 12:03 AM ISTErtugliflozin is a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), is an approved glucose-lowering therapy in type 2 diabetes mellitus....
ACEI/ARB, SGLT2 inhibitors combo better for diabetes control than ACEI/ARB alone: Study Medha Baranwal7 March 2021 7:00 PM ISTChina: The combo of SGLT2 inhibitors and ACEI/ARB is effective and well-tolerated than ACEI/ARB alone in patients with type 2 diabetes (T2D),...
Adding SGLT2 inhibitors to GLP-IRA therapy imparts CV benefit in diabetics: Circulation Medha Baranwal8 Jan 2021 8:07 PM ISTUSA: Initiation of SGLT2i versus sulfonylureas in diabetes patients on GLP-1RA therapy confers greater cardiovascular benefit, suggests a recent study...
SGLT2 inhibitors lowers risk of atrial fibrillation: Review Medha Baranwal4 Jan 2021 6:00 PM ISTUSA: People treated with SGLT2 inhibitors are at significantly lower risk of developing atrial fibrillation (AF), suggests a recent review in the...
DPP-4 inhibitors and SGLT2 inhibitors effective in diabetics after kidney transplant Medha Baranwal26 Dec 2020 12:30 PM ISTGreece:Evidence regarding the utilization of DPP-4 inhibitors and particularly SGLT2 inhibitors and GLP-1 receptor agonists is limited in renal...
Empagliflozin plus loop diuretics significantly increase urine volume in diabetes with HF Medha Baranwal10 Nov 2020 10:15 AM ISTUK: The use of SGLT2 inhibitor empagliflozin in combination with loop diuretics in patients with type 2 diabetes (T2D) and heart failure, helps in...
Dapagliflozin Going Off Patent with a Slashed Price Hina Zahid3 Nov 2020 11:30 AM ISTDiabetes is well-known to adversely impact the heart, vascular system and renal system. The patients with type 2 diabetes mellitus (T2DM) are at...
Canagliflozin reduces anemia risk in patients with CKD and diabetes: Lancet Medha Baranwal30 Oct 2020 6:00 PM ISTAustralia: Patients with chronic kidney disease (CKD) and type 2 diabetes who received SGLT2 inhibitor canagliflozin had a lower risk of...
Empagliflozin may reduce hospitalization and death risk in heart failure: Study Dr Satabdi Saha26 Oct 2020 8:00 AM ISTAccording to a recent research, patients receiving empagliflozin therapy for heart failure, showed a lower risk of cardiovascular death or...
Empagliflozin lowers death risk in HF in non Diabetics also: NEJM Medha Baranwal17 Oct 2020 10:30 AM ISTUSA: The use of SGLT2 inhibitor empagliflozin in heart failure patients lowers the risk of cardiovascular death and hospitalization for...
Two groups of blood sugar control drugs significantly reduce CKD and CVD risk- AHA Dr. Kamal Kant Kohli29 Sept 2020 8:00 AM ISTDALLAS - Two newer groups of antidiabetic medications prescribed primarily for Type 2 diabetes treatment (SGLT2 inhibitors and GLP-1 receptor...
SGLT2 Inhibitors tied to lower CV risk relative to DPP-4 Inhibitors in Diabetes: BMJ Dr. Kamal Kant Kohli24 Sept 2020 9:56 AM ISTPrevious trials have shown that SGLT2 inhibitors can reduce the risk of heart conditions such as heart attack, stroke, and heart failure compared with...
